Company Profile
Theralase Technologies Inc., a clinical stage pharmaceutical company provides the research, development, and commercialization of energy activated small molecules and associated drug formulations globally.
The company operates in two segments, Drug Division and Device Division. It engages in the R&D of Rutherrin, an injectable form of Ruvidar for the treatment of glio blastoma multiforme, a form of brain cancer, non-small cell lung cancer, pancreatic cancer, colorectal cancer, and muscle invasive bladder cancer
Ruvidar, a topical treatment for herpes simplex virus-1 lesions and an extracorporeal treatment for lymphoma, leukemia, and multiple myeloma. It also researches, develops, manufactures, and distributes Cool Laser Therapy systems to healthcare practitioners for the healing of pain. Theralase Technologies Inc. is based in Toronto, Canada.